Last reviewed · How we verify
Giovana Maria Weckwerth — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Surgery with Naproxen | Surgery with Naproxen | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | Pain Management / Perioperative Care | |
| Surgery with Naproxen and Esomeprazole | Surgery with Naproxen and Esomeprazole | marketed | NSAID + Proton pump inhibitor combination | COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) | Pain management / Gastroenterology |
Therapeutic area mix
- Pain Management / Perioperative Care · 1
- Pain management / Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Sanofi · 2 shared drug classes
- Amneal Pharmaceuticals, LLC · 1 shared drug class
- Bayer · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Amzell · 1 shared drug class
- Actavis Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Giovana Maria Weckwerth:
- Giovana Maria Weckwerth pipeline updates — RSS
- Giovana Maria Weckwerth pipeline updates — Atom
- Giovana Maria Weckwerth pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Giovana Maria Weckwerth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/giovana-maria-weckwerth. Accessed 2026-05-16.